Industry news

Bruker has unveiled major enhancements across its MALDI Biotyper® and IR Biotyper® portfolios at ESCMID Global 2026, including the launch of the new MBT Easy T® Kit, expanded reference libraries covering more than 5,300 species, and early access to a cloud-based identification solution. The updates strengthen Bruker’s microbial identification, outbreak management, and reflex NGS typing workflows for laboratories tackling evolving infectious disease challenges.

mzio GmbH has secured two new grants to fund growth and product development, and will launch FAIR-MS, its AI-powered software for the comparative analysis and reuse of historical mass spectrometry data, at ASMS 2026. The Bremen-based biotech software company will also unveil major updates to its mzmine platform, alongside three scientific posters at the conference.

AI-powered smart glasses designed to support dementia patients win the £1 million Longitude Prize award.

New report warns UK risks losing billions in science investment without stronger research infrastructure support.

A smart IUD with internal sensors could unlock real-time insights into fertility, endometriosis and uterine health.

Government unveils major cancer reform plan promising faster diagnosis, expanded genomic testing and improved survival outcomes across England.

AI-powered microscopy platform tracks individual cells through full life cycles, accelerating single-cell analysis and reducing manual image processing workloads.

New trap-based microfluidic technology detects PFAS in minutes, eliminating filtration steps and simplifying environmental laboratory workflows.

An international research project is testing whether a simple finger-prick blood test could detect Alzheimer’s biomarkers, potentially transforming diagnosis.

Groundbreaking brain cancer implant therapy attracts £4.5m investment, advancing innovation in targeted treatment and neuromedical technology.

The UK’s first Category 3 robotic AI lab has begun its first commercial vaccine research collaboration, showcasing automated science and global innovation potential.

Public consultation opens on targeted prostate cancer screening recommendations – shaping future UK policy for early detection and high-risk groups.

Warwick Science Park expands lab facilities – easing space shortages and strengthening the Midlands as a rising hub for UK research.

Great labs aren’t built on equipment alone – they thrive on communication, trust, and real appreciation among the people doing the work.

The International Association for the Study of Lung Cancer (IASLC) Pathology Committee has proposed a new, simplified grading system for invasive lung squamous cell carcinoma

Ataraxis AI, a laboratory pioneering AI-powered oncology tools, has announced a strategic collaboration with Medica Scientia Innovation Research (MEDSIR) to bring artificial intelligence into international

A breakthrough peptide fragment could stabilise Parkinson’s-linked proteins, preventing toxic clumps and restoring movement in early animal models.

Devon’s Smooth Snake population is rising fast thanks to conservation efforts, habitat restoration, and dedicated volunteers safeguarding heathlands.

A £6 million NIHR-funded platform will allow NHS trusts to test AI screening tools nationwide, cutting costs and delays.

New NHS procurement strategy prioritises patient outcomes, safety, and long-term value over lowest price, opening doors for medtech innovation.

Researchers identify sClever-1 as a hidden protein undermining immunotherapy — and show a new antibody may restore treatment effectiveness.

A £15bn funding plan could generate 1,700 new spin-outs and 56,000 jobs — if investment spreads beyond the ‘golden triangle’.

Oral microbes, including Candida fungi, may triple pancreatic cancer risk — offering new potential for early screening and personalised prevention strategies.

The NHS will offer a free gonorrhoea vaccine to high-risk patients from August 2025, aiming to curb record infections and antibiotic resistance.

US health secretary Robert F Kennedy Jr will cancel 22 mRNA vaccine projects, redirecting US$0.5 billion to alternative platforms he claims are safer.